Monoclonal antibodyFDA-approvedFirst-line
Pertuzumab
How it works
Binds the HER2 receptor on cancer cells, blocking growth signals and flagging the cells for immune destruction.
Cancer types
Breast Cancer— HER2-positive
Efficacy
In clinical trials, pertuzumab improved progression-free survival in patients with HER2-positive metastatic breast cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Tucatinib and Trastuzumab-Pertuzumab for Metastatic HER2+ Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Real-world Study of a Breast Cancer Treatment | Breast Cancer | preclinical | — | Source → |
| Study of Atezolizumab, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer with Brain Metastases | Breast Cancer | phase-2 | — | Source → |
| Testing T-DM1 and Pertuzumab in Early-Stage HER2+ Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Pertuzumab and Trastuzumab Combination Shows Promise in Urothelial Cancer | Ovarian Cancer | phase-2 | The disease control rate was 37% in the urothelial cancer cohort. | Source → |
| Pertuzumab Improves Cancer Treatment Response in Early HER2+ Breast Cancer | Breast Cancer | meta-analysis | The pooled odds ratio showed significantly higher pathological complete response rates with dual HER2 blockade (OR: 1.81; 95% CI: 1.56-2.09) | Source → |
| Dual HER2 Blockade Improves Outcomes in HER2-Positive Breast Cancer | Breast Cancer | meta-analysis | The P + H arm showed significant improvements in 3-year EFS rate (RR 1.08, 95% CI 1.00-1.16, p = 0.04), 5-year EFS rate (RR 1.10, 95% CI 1.01-1.20, p = 0.03), and 5-year DFS rate (RR 1.09, 95% CI 0.99-1.20). | Source → |
| Subcutaneous Trastuzumab/Pertuzumab Shortens Patient Treatment Time | Breast Cancer | phase-2 | SC administration of HP shortened patient time burden by approximately 1 hour. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.